159 related articles for article (PubMed ID: 9809552)
1. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma.
King CA; Spellerberg MB; Zhu D; Rice J; Sahota SS; Thompsett AR; Hamblin TJ; Radl J; Stevenson FK
Nat Med; 1998 Nov; 4(11):1281-6. PubMed ID: 9809552
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C.
Spellerberg MB; Zhu D; Thompsett A; King CA; Hamblin TJ; Stevenson FK
J Immunol; 1997 Aug; 159(4):1885-92. PubMed ID: 9257853
[TBL] [Abstract][Full Text] [Related]
3. Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies.
Savelyeva N; Munday R; Spellerberg MB; Lomonossoff GP; Stevenson FK
Nat Biotechnol; 2001 Aug; 19(8):760-4. PubMed ID: 11479570
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma.
Thirdborough SM; Radcliffe JN; Friedmann PS; Stevenson FK
Cancer Res; 2002 Mar; 62(6):1757-60. PubMed ID: 11912151
[TBL] [Abstract][Full Text] [Related]
5. DNA fusion gene vaccines against cancer: from the laboratory to the clinic.
Stevenson FK; Rice J; Ottensmeier CH; Thirdborough SM; Zhu D
Immunol Rev; 2004 Jun; 199():156-80. PubMed ID: 15233733
[TBL] [Abstract][Full Text] [Related]
6. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
[TBL] [Abstract][Full Text] [Related]
7. Escherichia coli-based production of a tumor idiotype antibody fragment--tetanus toxin fragment C fusion protein vaccine for B cell lymphoma.
Patel KG; Ng PP; Levy S; Levy R; Swartz JR
Protein Expr Purif; 2011 Jan; 75(1):15-20. PubMed ID: 20851769
[TBL] [Abstract][Full Text] [Related]
8. A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines.
Hakim I; Levy S; Levy R
J Immunol; 1996 Dec; 157(12):5503-11. PubMed ID: 8955200
[TBL] [Abstract][Full Text] [Related]
9. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells.
Fredriksen AB; Sandlie I; Bogen B
Mol Ther; 2006 Apr; 13(4):776-85. PubMed ID: 16414309
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles.
Pai Kasturi S; Qin H; Thomson KS; El-Bereir S; Cha SC; Neelapu S; Kwak LW; Roy K
J Control Release; 2006 Jul; 113(3):261-70. PubMed ID: 16793161
[TBL] [Abstract][Full Text] [Related]
11. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
12. Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection.
Benvenuti F; Burrone OR; Efremov DG
Gene Ther; 2000 Apr; 7(7):605-11. PubMed ID: 10819576
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
14. Identification and assembly of V genes as idiotype-specific DNA fusion vaccines in multiple myeloma.
Sahota SS; Townsend M; Stevenson FK
Methods Mol Med; 2005; 113():105-19. PubMed ID: 15968098
[TBL] [Abstract][Full Text] [Related]
15. Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses.
Forconi F; King CA; Sahota SS; Kennaway CK; Russell NH; Stevenson FK
Immunology; 2002 Sep; 107(1):39-45. PubMed ID: 12225361
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
[TBL] [Abstract][Full Text] [Related]
17. [The experimental study on idiotypic DNA vaccine against human B-cell lymphoma to induce antitumor immune response].
Zhong KL; Zhang WJ; Yuan Y; Wu Y; Zhang MW; Mao N
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):609-15. PubMed ID: 14706145
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.
Savelyeva N; King CA; Vitetta ES; Stevenson FK
Proc Natl Acad Sci U S A; 2005 Aug; 102(31):10987-92. PubMed ID: 16037207
[TBL] [Abstract][Full Text] [Related]
19. Anti-lymphoma immunity: relative efficacy of peptide and recombinant DNA vaccine.
Lim SY; Laxmanan S; Stuart G; Ghosh SK
Cancer Detect Prev; 2001; 25(5):470-8. PubMed ID: 11718453
[TBL] [Abstract][Full Text] [Related]
20. DNA vaccines against haematological malignancies.
Stevenson FK; King CA; Spellerberg MB; Zhu D; Rice J; Sahota S; Thompsett A; Radl J; Hamblin TJ
Haematologica; 1999 Jun; 84 Suppl EHA-4():11-3. PubMed ID: 10907456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
